法国EPIPAGE-2队列5岁极早产儿视力评估研究解读
本文解读法国全国性EPIPAGE-2队列研究,对象为胎龄22–34周的极早产儿,在5.5岁时评估视力与神经发育的关系。结果显示视力未达最佳的比例较高,且视力受损儿童更易出现认知、运动和行为问题。EPIPAGE-2较EPIPAGE-1显示死亡率下降、不良结局发生率降低。
要点
- 极早产儿5.5岁时视力未达最佳的比例较高。
- 视力受损与认知、运动及行为发育困难风险增加相关。
- EPIPAGE-2较EPIPAGE-1生存者死亡率及不良结局率下降。
核心结论
- 极早产儿在5.5岁时视力未达最佳的比例较高。
- 视力未达最佳的儿童出现认知、运动功能和行为问题的风险增加。
研究设计与样本
- 基于法国全国性EPIPAGE-2队列研究,纳入27个法国地区5169例活产儿,覆盖胎龄22–34周活产儿约98%。
主要发现
- EPIPAGE-2生存者较EPIPAGE-1死亡率更低,不良结局发生率也更低。
- 视力未达最佳与神经发育困难(包括认知、运动功能和行为问题)相关。
- EPIPAGE-1纳入法国9个地区胎龄22–32周的全部早产儿。
关键数值与推荐
- EPIPAGE-2纳入5169例胎龄22–34周的活产儿。
- EPIPAGE-1纳入胎龄22–32周早产儿。
- 视力与神经发育关联评估年龄为5.5岁。
临床怎么用
- 对极早产儿随访至5.5岁时应常规关注视力发育情况。
- 发现视力未达最佳时应评估认知、运动和行为等方面的发育风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yaman Hendi with co-authors present results from the French nationwide EPIPAGE-2 study 1 on the relation between visual acuity and neurodevelopment at 5.5 years in children born very preterm. The investigators demonstrate a high prevalence of suboptimal visual acuity and also that affected children are at increased risk of neurodevelopmental difficulties including cognition, motor function and behavioural problems. The EPIPAGE-2 study is a major national collaborative achievement initiated in 2011, following up on the population-based EPIPAGE-1 study from 1997. Multiple scientific reports have been published from both studies, also demonstrating decreased mortality and lower rates of adverse outcomes in the EPIPAGE-2 survivors compared with EPIPAGE-1. 2 The EPIPAGE-1 study included all preterm infants with GA 22–32 weeks from nine regions in France, while the EPIPAGE-2 study included 5169 live-births in 27 French regions representing 98% of all live-born infants with GA 22–34 weeks during a 6- to...
引用
- ADC Fetal and Neonatal:Visual acuity assessments at 5 years in a national cohort (EPIPAGE-2)
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。